Cargando…
Response to pazopanib‐based combination regimen in a case of FGFR3 amplified gastric adenocarcinoma
Angiogenesis inhibitors (AGI) are not presently used for the treatment of gastric cancers. This report demonstrates that angiogenesis inhibitor can be safely and effectively used in combination with cytotoxic anti‐cancer agents for treatment of Gastric cancers.
| Autores principales: | , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8572349/ https://www.ncbi.nlm.nih.gov/pubmed/34765202 http://dx.doi.org/10.1002/ccr3.4986 |
| _version_ | 1784595196561850368 |
|---|---|
| author | Limaye, Sewanti Patil, Darshana Akolkar, Dadasaheb Srivastava, Navin Patil, Revati Apurwa, Sachin Patil, Sanket John, Jinumary Gosavi, Rahul Nesargikar, Prabhu Kumar, Prashant Datta, Vineet Bose, Chirantan Raazi, Zarrine Srinivasan, Ajay Datar, Rajan |
| author_facet | Limaye, Sewanti Patil, Darshana Akolkar, Dadasaheb Srivastava, Navin Patil, Revati Apurwa, Sachin Patil, Sanket John, Jinumary Gosavi, Rahul Nesargikar, Prabhu Kumar, Prashant Datta, Vineet Bose, Chirantan Raazi, Zarrine Srinivasan, Ajay Datar, Rajan |
| author_sort | Limaye, Sewanti |
| collection | PubMed |
| description | Angiogenesis inhibitors (AGI) are not presently used for the treatment of gastric cancers. This report demonstrates that angiogenesis inhibitor can be safely and effectively used in combination with cytotoxic anti‐cancer agents for treatment of Gastric cancers. |
| format | Online Article Text |
| id | pubmed-8572349 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | John Wiley and Sons Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-85723492021-11-10 Response to pazopanib‐based combination regimen in a case of FGFR3 amplified gastric adenocarcinoma Limaye, Sewanti Patil, Darshana Akolkar, Dadasaheb Srivastava, Navin Patil, Revati Apurwa, Sachin Patil, Sanket John, Jinumary Gosavi, Rahul Nesargikar, Prabhu Kumar, Prashant Datta, Vineet Bose, Chirantan Raazi, Zarrine Srinivasan, Ajay Datar, Rajan Clin Case Rep Case Report Angiogenesis inhibitors (AGI) are not presently used for the treatment of gastric cancers. This report demonstrates that angiogenesis inhibitor can be safely and effectively used in combination with cytotoxic anti‐cancer agents for treatment of Gastric cancers. John Wiley and Sons Inc. 2021-11-07 /pmc/articles/PMC8572349/ /pubmed/34765202 http://dx.doi.org/10.1002/ccr3.4986 Text en © 2021 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Case Report Limaye, Sewanti Patil, Darshana Akolkar, Dadasaheb Srivastava, Navin Patil, Revati Apurwa, Sachin Patil, Sanket John, Jinumary Gosavi, Rahul Nesargikar, Prabhu Kumar, Prashant Datta, Vineet Bose, Chirantan Raazi, Zarrine Srinivasan, Ajay Datar, Rajan Response to pazopanib‐based combination regimen in a case of FGFR3 amplified gastric adenocarcinoma |
| title | Response to pazopanib‐based combination regimen in a case of FGFR3 amplified gastric adenocarcinoma |
| title_full | Response to pazopanib‐based combination regimen in a case of FGFR3 amplified gastric adenocarcinoma |
| title_fullStr | Response to pazopanib‐based combination regimen in a case of FGFR3 amplified gastric adenocarcinoma |
| title_full_unstemmed | Response to pazopanib‐based combination regimen in a case of FGFR3 amplified gastric adenocarcinoma |
| title_short | Response to pazopanib‐based combination regimen in a case of FGFR3 amplified gastric adenocarcinoma |
| title_sort | response to pazopanib‐based combination regimen in a case of fgfr3 amplified gastric adenocarcinoma |
| topic | Case Report |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8572349/ https://www.ncbi.nlm.nih.gov/pubmed/34765202 http://dx.doi.org/10.1002/ccr3.4986 |
| work_keys_str_mv | AT limayesewanti responsetopazopanibbasedcombinationregimeninacaseoffgfr3amplifiedgastricadenocarcinoma AT patildarshana responsetopazopanibbasedcombinationregimeninacaseoffgfr3amplifiedgastricadenocarcinoma AT akolkardadasaheb responsetopazopanibbasedcombinationregimeninacaseoffgfr3amplifiedgastricadenocarcinoma AT srivastavanavin responsetopazopanibbasedcombinationregimeninacaseoffgfr3amplifiedgastricadenocarcinoma AT patilrevati responsetopazopanibbasedcombinationregimeninacaseoffgfr3amplifiedgastricadenocarcinoma AT apurwasachin responsetopazopanibbasedcombinationregimeninacaseoffgfr3amplifiedgastricadenocarcinoma AT patilsanket responsetopazopanibbasedcombinationregimeninacaseoffgfr3amplifiedgastricadenocarcinoma AT johnjinumary responsetopazopanibbasedcombinationregimeninacaseoffgfr3amplifiedgastricadenocarcinoma AT gosavirahul responsetopazopanibbasedcombinationregimeninacaseoffgfr3amplifiedgastricadenocarcinoma AT nesargikarprabhu responsetopazopanibbasedcombinationregimeninacaseoffgfr3amplifiedgastricadenocarcinoma AT kumarprashant responsetopazopanibbasedcombinationregimeninacaseoffgfr3amplifiedgastricadenocarcinoma AT dattavineet responsetopazopanibbasedcombinationregimeninacaseoffgfr3amplifiedgastricadenocarcinoma AT bosechirantan responsetopazopanibbasedcombinationregimeninacaseoffgfr3amplifiedgastricadenocarcinoma AT raazizarrine responsetopazopanibbasedcombinationregimeninacaseoffgfr3amplifiedgastricadenocarcinoma AT srinivasanajay responsetopazopanibbasedcombinationregimeninacaseoffgfr3amplifiedgastricadenocarcinoma AT datarrajan responsetopazopanibbasedcombinationregimeninacaseoffgfr3amplifiedgastricadenocarcinoma |